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Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by a decline in cognitive 
functions with no validated disease modifying treatment. It is critical for timely treatment to detect 
AD in its earlier stage before clinical manifestation. Mild cognitive impairment (MCI) is an intermediate 
stage between cognitively normal older adults and AD. To predict conversion from MCI to probable 
AD, we applied a deep learning approach, multimodal recurrent neural network. We developed an 
integrative framework that combines not only cross-sectional neuroimaging biomarkers at baseline 
but also longitudinal cerebrospinal fluid (CSF) and cognitive performance biomarkers obtained from 
the Alzheimer’s Disease Neuroimaging Initiative cohort (ADNI). The proposed framework integrated 
longitudinal multi-domain data. Our results showed that 1) our prediction model for MCI conversion 
to AD yielded up to 75% accuracy (area under the curve (AUC) = 0.83) when using only single modality 
of data separately; and 2) our prediction model achieved the best performance with 81% accuracy 
(AUC = 0.86) when incorporating longitudinal multi-domain data. A multi-modal deep learning 
approach has potential to identify persons at risk of developing AD who might benefit most from a 
clinical trial or as a stratification approach within clinical trials.
Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disorder characterized by abnormal 
accumulation of amyloid plaques and neurofibrillary tangles in the brain, causing problems with memory, think-
ing, and behavior. AD is the most common form of dementia with no validated disease modifying treatment. An 
estimated 5.7 million Americans are living with AD in 2018. By 2050, this number is projected to rise to nearly 
14 million1. Current available treatments decelerate only the progression of AD and no treatment developed so 
far can cure a patient who is already in AD. Thus, it is of fundamental importance for timely treatment and pro-
gression delay to develop strategies for detection of AD at early stages before clinical manifestation. As a result, 
the concept of mild cognitive impairment (MCI) was introduced. MCI, a prodromal form of AD, is defined to 
describe people who have mild symptoms of brain malfunction but can still perform everyday tasks. Patients 
in the phase of MCI have an increased risk of progressing to dementia1–4. Some patients in their MCI stages are 
converted to AD within a limit of the time window after baseline, while some are not. It has been reported that 
MCI patients progress to AD at a rate of 10% to 15% per year and 80% of these MCI patients will have converted 
to AD after approximately six years of follow-up5,6. It is an ongoing topic among AD-related researches to identify 
biomarkers that classify patients with MCI who later progress to AD (MCI converter) from those with MCI who 
do not progress to AD (MCI non-converter).
Various machine learning methods have been applied to identify biomarkers for MCI conversion prediction 
and improve their performances. Support vector machine (SVM) is one of methods frequently used for solving 
classification problem. A lot of studies applied SVM for MCI conversion prediction7–12. A multi-task learning along 
with SVM was used to identify AD-relevant features, showing 73.9% accuracy, 68.6% sensitivity, and 73.6% specific-
ity7. For the use of additional subjects, a domain transfer learning method to use auxiliary samples such as AD and 
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cognitively normal older adults (CN) subjects as well as MCI subjects showed 79.4% accuracy, 84.5% sensitivity, and 
72.7% specificity8. A linear discriminant analysis (LDA) was used based on cortex thickness data showing 63% sensi-
tivity and 76% specificity13. Furthermore, the integration of multi-modality data improves the performance for MCI 
conversion prediction by extracting complementary AD-related biomarkers from each modality. Cerebrospinal fluid 
(CSF), MRI, and cognitive performance biomarkers were combined, resulting in 68.5% accuracy 53.4% sensitivity, 
and 77% specificity14,15. Along with MRI and CSF biomarkers, APOE ε4 status were integrated16.
In this study, in order to predict MCI to AD conversion, we proposed a multimodal recurrent neural network 
method, a deep learning approach, based on the integration of demographic information, longitudinal CSF bio-
markers, longitudinal cognitive performance, and cross-sectional neuroimaging biomarkers at baseline obtained 
from the Alzheimer’s Disease Neuroimaging Initiative cohort (ADNI). Our proposed deep learning method can 
incorporate longitudinal multiple domain data and take variable-length longitudinal data to capture temporal 
features at multiple time points. In particular, non-overlapping samples as well as overlapping samples from each 
data can be used to build a prediction model.
Results
Study participants. All individuals used in the analysis were participants of the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI)17,18. The overall goal of ADNI is to test whether serial magnetic resonance imag-
ing (MRI), position emission tomography (PET), other biological markers, and clinical and neuropsychological 
assessment could be combined to measure the progression of MCI and early AD. Demographic information, raw 
neuroimaging scan data, APOE genotype, CSF measurements, neuropsychological test scores, and diagnostic 
information are publicly available from the ADNI data repository (http://adni.loni.usc.edu). Informed consent 
was obtained for all subjects, and the study was approved by the relevant institutional review board at each data 
acquisition site (for up-to-date information, see http://adni.loni.usc.edu/wp-content/themes/freshnews-dev-v2/
documents/policy/ADNI_Acknowledgement_List%205-29-18.pdf). All methods were performed in accordance 
with the relevant guidelines and regulations. In this study, a total of 1,618 ADNI participants aged 55 to 91 were 
used, which include 415 cognitively normal older adult controls (CN), 865 MCI (307 MCI converter and 558 MCI 
non-converter), and 338 AD patients (Table 1).
We used four different types, or modalities of data: demographic information, neuroimaging phenotypes 
measured by MRI, cognitive performance, and CSF measurements. Demographic information includes age, 
sex, years of education, and APOE ε4 status. Cognitive performance includes composite scores for executive 
functioning (ADNI-EF) and memory (ADNI-MEM) derived from the ADNI neuropsychological battery using 
item response theory as described in detail elsewhere19. CSF biomarkers for AD include amyloid-β 1–42 peptide 
(Aβ1–42), total tau (t-tau), and tau phosphorylated at the threonine 181 (p-tau). AD-related neuroimaging bio-
markers measured by MRI include hippocampal volume and entorhinal cortical thickness.
Experimental setting. To evaluate the performance and effectiveness of our proposed longitudinal 
multi-modal deep learning method, we used three schemes and compared their performances (Table 2). In the 
experiment named “baseline”, 4 modalities data at baseline visit (cognitive performance, CSF, demographic infor-
mation, and MRI) were incorporated. In “single modal”, only longitudinal cognitive performance data was used 
for the predictor (we tried all other single modality, and the performance with cognitive scores was the best). 
Finally, the four modalities of longitudinal data were combined and used for training the classifier in the exper-
iment marked as “proposed”. Table 3 shows summary statistics of each modalities of data and hyperparameters 
used for training GRUs.
For training our models, subjects in CN and AD groups are used as well as MCI-C and MCI-NC. This 
approach is motivated by8,10,11,20–22. They use CN and AD subjects for training a classifier such as SVM23 or locally 
linear embedding (LLE)24, and then the classifier is used for classification of MCI-C and MCI-NC. In our exper-
iment, CN and AD are used as auxiliary dataset to pre-train the classifier, and then MCI-C and MCI-NC are also 
used for training.
Characteristics
MCI-C
(n = 307)
MCI-NC 
(n = 558)
CN
(n = 415)
AD
(n = 338)
Sex (Female/Male) 117/190 236/322 206/209 152 /186
Memory score (mean ± sd) −0.26 ± 0.5 0.39 ± 0.64 1.01 ± 0.56 −0.86 ± 0.54
Education (mean ± sd) 15.89 ± 2.75 15.94 ± 2.88 16.28 ± 2.72 15.15 ± 2.99
APOE ε4 (0/1/2) 105/153/49 325/188/45 301/103/11 113/160/65
Table 1. Subject demographics at baseline visit.
Longitudinal data Multimodal data Representation
✓ baseline
✓ single modal
✓ ✓ proposed
Table 2. Three experimental schemes depending on training dataset composition.
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We tested the classifier on MCI patients to predict the conversion after Δt from baseline (6, 12, 18, and 24 
months) as shown in Fig. 1. Due to the nature of our data the sample size available for training varies over Δt 
(Fig. 2). For example, if AD occurs early from the baseline visit, then we have relatively fewer training samples 
because we have a smaller data window to predict on. At each prediction time (Δt), we ran 5-fold cross-validation 
10 times in which every fold has the same ratio of MCI-C and MCI-NC subjects. MCI samples were partitioned 
into 5 subsets, and one subset was selected for testing, while the remaining subsets were used for training.
Comparison of prediction of MCI to AD conversion using cross-sectional data at baseline and 
longitudinal data. To evaluate the advantage of using longitudinal data, we first compared the performances 
of two schemes: “baseline” and “proposed” (Figs 3 and 4). Intuitively, data from multiple time points has more 
information than data at a single time point. Thus, the GRU analyzes the temporal changes in cognitive perfor-
mance and CSF to extract features (which are not contained in baseline visit data) for the correct MCI conversion 
prediction. As shown in Table 4(a,b), the prediction model based on longitudinal data shows better performance 
than the model using only cross-sectional data at baseline. In particular, sensitivity is an important measure for 
the prediction task in which identifying true positive rate is crucial25. In prediction of MCI conversion, a classifier 
with higher true positive rate is more applicable for timely treatment.
#Features
Hidden 
Dimension
Time length 
(Average)
Time length 
(sd)
Cognitive performance 2 3 3.7 1.32
Demographic Information 4 5 1 0
CSF 5 6 1.4 0.5
MRI 3 4 1 0
Table 3. Summary statistics for data and hyperparameters.
Figure 1. An example using longitudinal data for MCI conversion prediction. Contrary to the experiment 
with baseline visit data, longitudinal data of individuals in all stages (CN, MCI, and AD) was used for training a 
classifier. Then, portion of longitudinal data was taken to the classifier to predict AD progression after Δt.
Figure 2. The number of subjects available in demographic data, neuroimaging data, cognitive performance, 
and CSF biomarkers over ∆t.
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Comparison of prediction of MCI to AD conversion using single modal and multimodal data. 
For evaluating the effectiveness of multimodal data integration, we compared the performances of “proposed” 
and “single modal” experiments. Figure 3 shows the accuracies of “proposed” and models with single modality of 
data. We removed the accuracy from the model with demographic data because the prediction performance was 
too low. The model using cognitive performance was observed to be the most accurate among models that use 
each single modality of data. Even though the sample size for neuroimaging data was larger than those of cogni-
tive performance and CSF biomarkers (Fig. 3), the model with neuroimaging data showed less accuracy. This is 
because cognitive performance is a longitudinal data which takes advantage of giving relatively closer data record 
to MCI conversion point. However, model with cognitive performance shows extremely high variance of sensi-
tivity for predicting 18 and 24 months. It is observed that model only with cognitive performance not a stable pre-
dictor for long period of prediction while integrating other biomarkers can alleviate the high variance in proposed.
Figure 3. Predictive performances with “proposed”, “baseline”, and “single modal”. Abbreviations: COG: 
cognition performance biomarkers; CSF: cerebrospinal fluid biomarkers; NeuroImg: MRI biomarkers.
Figure 4. ROC curves from the “proposed”, “baseline”, and each “single modal” method. (a) 6 month prediction. 
(b) 12 month prediction. (c) 18 month prediction. (d) 24 month prediction.
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Discussion
We proposed an integrative approach for the prediction of MCI to AD conversion using a deep learning approach, 
more specifically, a multi-modal recurrent neural network. Our method takes advantages of longitudinal and 
multi-modal nature of available data to discover nonlinear patterns associated with MCI progression. To evalu-
ate the advantages of our proposed method, we compared performance outputs from three schemes: “baseline”, 
“single modal”, and “proposed”. As observed in Fig. 4, “baseline” and “single modal” with cognitive test biomark-
ers show similar performances over prediction periods. Using longitudinal data or combining multimodal data 
are effective ways for increasing predictive power thus, it seems natural for combining longitudinal multimodal 
data (“proposed”) to show the best performance. In Table 5, as predicted further periods, the reliability of per-
formance improvement is lower due to the lack of positive samples. However, specificities of proposed model 
showed enhanced performance over competing methods consistently. In addition, the prediction results of our 
model were compared to those of previous studies with machine learning approaches (Table 6). Our method 
showed comparable prediction ability even though we had a highly unbalanced ratio of positive and negative 
samples. Specifically, the sensitivity of our model shows higher performance while specificity is lower. Moreover, 
The balanced accuracy26, which is a measure of accuracy considering sensitivity and specificity shows 0.82 for our 
model and 0.81 for27.
The biggest advantage of our approach is that irregular longitudinal data can be used. One of the major prob-
lems when dealing with longitudinal data is that a preprocessing step is required for handling variable-length of 
sequential data and missing values. In previous studies, the fixed length of time points was collected by taking data 
that fell within a certain time window. Additionally, an additional feature extraction phase is required to produce 
a fixed-size feature representation. In the first training step, separate GRU components make an encoding process, 
where longitudinal data are transformed into a vector containing AD-sensitive features. Thanks to the structure of 
GRU, our approach is capable of accepting any irregular length of data as an input without preprocessing.
In addition, our method can make full use of available subjects from each modality for training our clas-
sifier. This is a huge advantage in the face of data scarcity. As seen in Fig. 2, the number of subjects with CSF 
data is smallest in the overlapping sample. Traditional approaches can use only the overlapping samples while 
non-overlapping samples were abandoned. In our case, non-overlapping samples contribute to training the indi-
vidual GRU component it belongs to for the better representation learning. Furthermore, additional modality 
data are easily integrated into the model. Contrary to the kernel-based integration, concatenation-based integra-
tion method can incorporate other domains of data such as multi-modal neuroimaging and genomic data with-
out any prior knowledge. Thus, next we will integrate multi-modal neuroimaging and genomics data for learning 
features that might be useful in predicting early MCI to AD conversion.
Although there are some strengths as described above, our approach has some limitations. In the first train-
ing step, the input of each modality was transformed into a feature vector that is optimized for MCI conversion 
prediction only by single modality. Thus, features that are irrelevant to AD progression with respect to the single 
modality will be filtered out. However, if there are features that cannot be extracted by single modality but only can 
be explained by a combination of multi-modality of data then those are also likely to be filtered out. This is because 
parameters in GRUs are not updated against the final prediction result. In other words, parameter optimization 
for the second training step does not affect the parameters in each GRU for feature extraction, thus each GRU 
cannot learn from the final prediction based on the combined features. To solve this problem, we will link GRUs 
to logistic regressions at the second step so that GRU learns feature representation from multi-modality as well as 
single modality. In addition, we plan to modify the structure of our model making it possible for individual GRU 
components to extract integrative features. We are currently investigating this possibility as a sequel to this work.
Methods
Recurrent Neural Network. Recurrent Neural Network (RNN) is a class of deep learning architecture used 
when sequential data can be considered. In natural language processing (NLP), speech recognition, and anomaly 
detection in time series, RNN is popularly used for analyzing the sequence of words and time series data28. The 
advantage of applying RNN is that variable-length sequence can be processed to exploit temporal patterns hidden 
Δt 6 m 12 m 18 m 24 m
(a) Multimodal longitudinal data (proposed)
ACC (mean ±sd) 0.81 ± 0.03 0.81 ± 0.03 0.79 ± 0.03 0.80 ± 0.03
SEN (mean ± sd) 0.84 ± 0.07 0.84 ± 0.05 0.82 ± 0.07 0.81 ± 0.10
SPE (mean ± sd) 0.80 ± 0.04 0.80 ±  0.04 0.79 ± 0.04 0.80 ± 0.04
(b) Multimodal baseline visit data (baseline)
ACC (mean ±sd) 0.76 ± 0.03 0.76 ± 0.03 0.78 ± 0.03 0.76 ± 0.03
SEN (mean ± sd) 0.81 ± 0.07 0.82 ± 0.07 0.81 ± 0.07 0.80 ± 0.08
SPE (mean ± sd) 0.80 ± 0.04 0.75 ± 0.03 0.77 ± 0.05 0.76 ± 0.03
(c) Cognitive performance data (single modal)
ACC (mean ±sd) 0.74 ± 0.06 0.75 ± 0.05 0.74 ± 0.04 0.74 ± 0.04
SEN (mean ± sd) 0.81 ± 0.07 0.78 ± 0.14 0.76 ± 0.20 0.76 ± 0.20
SPE (mean ± sd) 0.75 ± 0.08 0.71 ± 0.05 0.71 ± 0.06 0.71 ± 0.06
Table 4. Prediction performance based on Δt over different schemes.
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in the given sequence. In the sentiment analysis task, for example, the goal is to classify the sentiment (good or 
bad) of a given sentence. The classifier needs to take a sentence (a sequence of words) as an input, understand the 
context in it, and return a correct sentiment as an output29. For the prediction task that detects initial diagnosis 
of heart failure in30, RNN takes time series of electronic health records (EHRs) using 12 to 18 month observation 
window. In these cases where variable-length input should be dealt with RNN is an appropriate candidate to use.
An RNN processes one element of an input sequence at a time and updates its memory state that implicitly 
contains information about the history of all the past elements of the sequence31. The hidden state is represented 
as a Euclidean vector (i.e., a sequence of real numbers) and is updated recursively from the input at the given step 
and the previous value of the hidden state (Fig. 5).
Suppose we have N number of subjects, each of which has a sequence … …x x x x{ , , , , , }n n t
n
T
n
1 2  where xi
n is a 
data record of n-th sample and the t-th element in a sequence and T is the length of the sequence. The corre-
sponding sequence of output is recursively computed as:
= +−h tanh W h W x( ) (1)t h t x t
n
1
σ=yˆ W h( ) (2)t y t
Model
accuracy 
(p-value)
sensitivity 
(p-value)
specificity 
(p-value)
(a) 6 month prediction.
Proposed 0.81 0.84 0.80
Baseline 0.76 (1.16e-08) 0.81 (0.07) 0.75 (1.87e-10)
Single modal (cognitive performance) 0.74 (3.17e-09) 0.81 (8.12e-05) 0.70 (2.68e-14)
Single modal (CSF) 0.72 (4.65e-17) 0.78 (8.12e-05) 0.70 (2.68e-14)
Single modal (MRI) 0.70 (4.68e-24) 0.75 (6.71e-10) 0.68 (2.05e-21)
(b) 12 month prediction
Proposed 0.81 0.84 0.80
Baseline 0.76 (1.77e-07) 0.82 (0.057) 0.75 (3.65e-07)
Single modal (cognitive performance) 0.75 (2.70e-08) 0.78 (0.007) 0.71 (1.73e-09)
Single modal (CSF) 0.73 (3.47e-20) 0.78 (1.40e-05) 0.72 (3.90e-16)
Single modal (MRI) 0.70 (7.29e-22) 0.73 (1.03e-12) 0.69 (2.07e-16)
(c) 18 month prediction
Proposed 0.79 0.82 0.79
Baseline 0.78 (0.08) 0.81 (0.64) 0.77 (0.15)
Single modal (cognitive performance) 0.74 (2.43e-06) 0.76 (0.03) 0.71 (7.72e-08)
Single modal (CSF) 0.72 (9.84e-12) 0.78 (0.07) 0.71 (6.55e-11)
Single modal (MRI) 0.72 (5.26e-14) 0.76 (0.16e-04) 0.71 (2.20e-10)
(d) 24 month prediction
Proposed 0.80 0.81 0.80
Baseline 0.76 (2.12e-05) 0.80 (0.57) 0.76 (8.95e-05)
Single modal (cognitive performance) 0.74 (4.69e-07) 0.76 (0.15) 0.72 (1.20e-09)
Single modal (CSF) 0.73 (1.06e-09) 0.73 (0.001) 0.74 (3.16e-07)
Single modal (MRI) 0.71 (1.18e-12) 0.76 (0.03) 0.70 (2.53e-10)
Table 5. Performance comparison between different models. P-values are calculated using a paired t-test 
between the proposed and each competing method.
Method
Subjects (MCI-C/
MCI-NC) Data source ACC SEN SPE
SVM7 43/48 MRI, PET, CSF 0.73 0.68 0.73
SVM8 43/56 MRI, FDG-PET, CSF 0.79 0.84 0.72
SVM9 35/50 MRI, PET, cognitive score 0.78 0.79 0.78
Gaussian process39 47/96 MRI, PET, CSF, APOE genotype 0.68 0.90 0.52
Hierarchical ensemble25 70/61 MRI 0.79 0.86 0.78
Deep neural network27 235/409 MRI, PET 0.82 0.79 0.83
Proposed 134/561 Cognitive score, MRI, CSF biomarker, demographic data 0.81 0.84 0.80
Table 6. A list of previous models that train a classifier mainly using MCI samples.
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Wh, Wx, and Wy are the weight matrices to extract task-specific features from the previous memory state ht−1, the 
t-th input xt and the current memory state ht, respectively. As can be seen from the equations, the memory states 
ht and the input xt are all represented as Euclidean vectors as well. Therefore, the dynamics of the entire RNN are 
captured by a sequence of matrix-vector multiplications, followed by elementwise non-linearity applications. The 
tanh function is a non-linear activation function taking the form of = −
+ −
tanh x( ) 1
e
2
1 x2
. The role of the 
non-linear activation function is to endow the RNN with higher representational power. yˆt is the predicted output 
resulting from the computation of the network. This final result is computed by the function σ, which is known as 
the softmax function. The role of the softmax function is to turn an arbitrary vector into a probability vector via 
the following operation:
σ =
∑
u e
e
( )i
u
k
u
i
k
where ui is the i-th element of the vector u. In equation (2), we abuse notation to express elementwise application 
of the above expression.
∑=
∈
ˆ ˆL y y
N
y logy( , )
1
(3)T n N
n T
n
= ˆ⁎ ⁎ ⁎W W W argmin L y y, , ( , )
(4)
h x y
W W W
T
, ,h x y
In our model, the last output sequence provided by the RNN is treated as the probability vector for classification, and 
the cross-entropy loss function (equation (3)) is used to quantify how “far away” our n-th prediction is from the n-th 
ground truth label yn. That is, we choose the optimal parameters ⁎ ⁎ ⁎W , W , Wh x y that minimize the cross-entropy loss 
of the given data (equation (4)). The algorithm we use to optimize the parameters is Backpropagation Through Time 
(BPTT)32, which updates the weights in the RNN to minimize the given loss function.
However, when the task requires long sequences of input to be processed, training an RNN is difficult33. This 
is called the long-term dependency problem. Variants of RNN such as Long Short-Term Memory (LSTM) and 
Gated Recurrent Unit (GRU) have been developed and practically used to solve this problem34,35. In the proposed 
model, we use GRU for each modality of data to process multiple time points of the input. The detailed structure 
of GRU is described in the supplementary.
Multi-modal GRU for MCI conversion prediction. Our problem can be considered as a sequential data 
classification. The classification objective is to predict whether an individual with MCI at baseline is converted to 
AD or not using sequence data, which consist of four modalities including cognitive performance, CSF, and MRI 
biomarkers as well as demographic information. Even though demographic data and MRI biomarkers are not 
longitudinal data we will consider them as length-one sequential data.
To apply a GRU-based classification algorithm to our problem, we need to design a model that can incorporate 
the four modalities of data. The main idea of our model is to separately build GRU feature extractors for each 
modality and integrate the extracted four feature vectors at the end. Our model is comprised of two training steps: 
(1) learning a single GRU for each modality of data, and (2) learning the integrative feature representation to 
make the final prediction. At the first training step, a single GRU is trained separately for each modality in which 
the classification objective is to predict conversion to AD from MCI. Using GRUs is essential to take longitudinal 
data and transform them into a fixed-size vector. This is quite similar to the approach proposed in36 that maps 
the input sequence into fixed-length representation. In the second step, MCI conversion is predicted based on 
the four vectors produced from each GRU components. For merging four vectors, we select concatenation-based 
data integration, which is conceptually the simplest method to integrate multiple sources of data into a single 
Figure 5. Illustration of recurrent neural network. RNN is composed of input, memory state, and output, each 
of which has a weight parameter to be learned for a given task. The memory state (blue box) takes the input 
and computes the output based on the memory state from the previous step and the current input (left). Since 
the RNN has a feedback loop, variable-length input and output sequence can be represented as an “unfolded” 
sequence (right).
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vector37. For the final prediction, l1-regularized logistic regression38 is used for the classification between MCI-C 
and MCI-NC. The overview of our proposed method is illustrated in Fig. 6.
Conclusion
Here, we proposed a multi-modal deep learning approach to study the prediction of MCI to AD conversion using 
longitudinal cognitive performance and CSF biomarkers as well as cross-sectional neuroimaging and demo-
graphic data at baseline. We applied multiple GRUs to use longitudinal multi-domain data and all subjects with 
each modality data. Our results showed that we achieved the better prediction accuracy of MCI to AD conversion 
by incorporating longitudinal multi-domain data. A multi-modal deep learning approach has potential to iden-
tify persons at risk of developing AD who might benefit most from a clinical trial or as a stratification approach 
within clinical trials.
Data Availability
Demogra phic information, neuroimaging data, APOE genotype, CSF measurements, neuropsychological test 
scores, and diagnostic information are publicly available from the ADNI data repository (http://adni.loni.usc.edu).
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